News

The SDNY on July 15, 2019, granted Marvel’s motion for summary judgment in a copyright infringement suit regarding an “Iron Man 3” movie poster.

The US Patent and Trademark Office on July 31, 2019, issued a federal register notice where it proposes to adjust patent fees; specifically, making several targeted fee adjustments in addition to an approximately five percent across the board increase to the fees.

The US Patent & Trademark Office is hosting a “Boardside Chat” webinar on Thursday, August 8, 2019, from noon to 1 p.m. ET about recent updates made to the AIA Trial Practice Guide.

The US Court of Appeals for the Federal Circuit on July 12, 2019, canceled a Patent Trial and Appeal Board decision upholding Infobridge Pte. Ltd.'s video coding patent (Patent No. 8,917,772) and sent it back to the board for review.

The Federal Circuit held that Ford Motor Company’s design patents for hood and head lamp designs on its F-150 trucks are valid because they aren’t functional, but ornamental.

The US District Court for the Central District of California on July 18, 2019, held that that Disney’s agreement with distributors to forbid downstream sales to Redbox does not violate copyright law.

The US Court of Appeals for the Federal Circuit on July 12, 2019, ruled that Dr. Reddy’s Laboratories Ltd. does not have to halt sales of its generic version of the opioid addiction treatment Suboxone Film. Indivior Inc. v. Dr. Reddy’s Laboratories, S.A., Fed. Cir., 17-2587, 7/12/19.

On July 17, 2019, a joint letter from AIPLA and other stakeholders was sent to US Secretary of State Michael Pompeo and US Secretary of Commerce Wilbur Ross supporting an appropriate elevation in rank for qualified USPTO Intellectual Property attachés.

The US Patent and Trademark Office will host its “Apollo 50: The role of intellectual property in space commerce” event on July 23, 2-4:30 pm EST at its headquarters in Alexandria, VA.

The US Patent and Trademark Office (USPTO) on July 15, 2019, published a second update to the AIA Trial Practice Guide (TPG) containing additional guidance about trial practice before the Patent Trial and Appeal Board (PTAB).

The United States Patent & Trademark Office published a new examination guide titled, "Examination of Specimens for Use in Commerce: Digitally Created or Altered and Mockup Specimens."

The US Court of Appeals for the Federal Circuit on July 10, 2019, held that General Electric Co.‘s position as a patent owner’s competitor was insufficient to establish standing to appeal a Patent Trial and Appeal Board decision.

The US Patent and Trademark Office on July 10, 2019, designated as precedential Focal Therapeutics, Inc. v. SenoRx, Inc., Case IPR2014-00116 (PTAB July 21, 2014) (Paper 19).

The IP Practice in China Committee delegation kicked of this year's trip with a dinner with Dennis Duncan, the USPTO IP Attache based in Beijing, who provided a briefing of current developments in China.

The US Court of Appeals for the Federal Circuit on July 5, 2019, held that the Patent Trial & Appeal Board must reexamine Global IP Holdings LLC’s bid to broaden the scope of its patent.

A split US Court of Appeals for the Federal Circuit, on July 3, 2019, refused to revisit their February decision to invalidate a patent licensed to Quest Diagnostics Inc.’s Athena unit for a way to diagnose a severe neurological disorder.

The US Patent and Trademark Office on June 3, 2019, published an examination guide explaining how the USPTO will examine trademark applications following the Supreme Court’s recent decision in Iancu v. Brunetti.

The US Patent and Trademark Office on July 2, 2019, issued final rules requiring foreign-domiciled trademark applicants, registrants, and parties to Trademark Trial and Appeal Board proceedings to be represented by an attorney who is licensed to practice law in the United States.

The June 2019 update of the USPTO’s Trademark Trial and Appeal Board Manual of Procedure (TBMP) is now available on the Trademark Trial and Appeal Board webpage under "Policies and procedures.

On June 25, 2019, the Federal Circuit held that a trial court wrongly dismissed Cellspin Soft, Inc.’s (Cellspin), patent infringement lawsuits after determining that the four disputed patents were invalid and covered an abstract idea.